Recently Featured

Lilly’s Jaypirca Receives CHMP Positive Opinion for CLL in Europe

July 15, 2026
Lilly has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukaemia (CLL) in adults. This decision marks a significant advancement in the therapeutic options available for CLL patients in Europe, particularly for those who…

Edison Scientific Formed to Drive AI in Biotech with $70 Million Funding

July 15, 2026
Edison Scientific, a new venture spun off from AI scientist company FutureHouse, has secured $70 million in funding to revolutionize drug discovery through artificial intelligence. This move comes as major pharmaceutical companies increasingly seek advanced AI solutions to enhance their research capabilities, highlighting a growing trend in the industry towards integrating cutting-edge technology into traditional…

Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration

July 15, 2026
Insilico Medicine has entered a significant partnership with SK Biopharmaceuticals to develop new AI-driven drug candidates targeting neuroimmune disorders of the central nervous system (CNS), a collaboration potentially worth up to $2.5 billion. This initiative underscores a growing trend in the pharmaceutical industry where AI technologies are increasingly being integrated into drug discovery processes. Under…

Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model

July 14, 2026
Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center have developed a promising intravesical CAR T-cell therapy targeting bladder cancer. Their preclinical study, co-led by Dr. Taha Merghoub, identified the protein MUC16 as a viable target for bladder cancer treatment. By delivering MUC16-targeting CAR T cells directly into the bladder via catheter, the…

Ongoing Cases